Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (886)	4/1/1998 2:09:00 PM
From: David Cathcart	Read Replies (3) \| Respond to of 1826

The subtitle from today's news release: "Salagen(R) Tablets is the First Prescription Pharmaceutical Available for Sjogren's Syndrome, an Autoimmune Disease Affecting Nearly 1 Million Americans" One million people! What do we think? 5%...10% of this market (@ $1000 per patient per year)? Last year, Joseph von Meister estimated $1/share in earnings for MOGN in 1999, based on the NCI and international partners paying for phase II development of MGI 114. Assuming MGI Pharma gets the European deal for MGI 114, I think they have a real shot at it the buck-per-share earnings next year. If they get a good European deal, we have a real shot at a $20 stock this year. David